Compare SRRK & TTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | TTEK |
|---|---|---|
| Founded | 2012 | 1966 |
| Country | United States | United States |
| Employees | N/A | 25000 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Military/Government/Technical |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 7.9B |
| IPO Year | 2018 | 1995 |
| Metric | SRRK | TTEK |
|---|---|---|
| Price | $47.76 | $31.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 3 |
| Target Price | ★ $56.17 | $44.00 |
| AVG Volume (30 Days) | 1.2M | ★ 2.4M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.82% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.76 |
| Revenue | N/A | ★ $2,964,148,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $534.24 | $6.43 |
| P/E Ratio | ★ N/A | $40.22 |
| Revenue Growth | N/A | ★ 7.66 |
| 52 Week Low | $27.07 | $25.81 |
| 52 Week High | $58.49 | $43.14 |
| Indicator | SRRK | TTEK |
|---|---|---|
| Relative Strength Index (RSI) | 39.63 | 62.26 |
| Support Level | $45.46 | $29.99 |
| Resistance Level | $48.23 | $32.38 |
| Average True Range (ATR) | 2.44 | 0.83 |
| MACD | -1.01 | -0.03 |
| Stochastic Oscillator | 6.24 | 73.67 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Tetra Tech Inc provides consulting and engineering services for environmental, infrastructure, resource management, energy, and international development markets. It specializes in providing water-related services for public and private clients. It designs infrastructure, facilities, and other structures with complex plans and resource management. it has two reportable segments. Its Government Services Group (GSG) segment includes activities with U.S. government clients (federal, state and local) and activities with development agencies world-wide. Commercial/International Services Group (CIG) segment, which derives maximum revenue, includes activities with U.S. commercial clients and international clients other than development agencies.